Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease

Neuromuscular Disorders

Volumn 19, Issue 2, 2009, Pages 113-117

  Van der Beek, N A M E ^a,b   Hagemans, M L C ^b   Reuser, A J J ^a   Hop, W C J ^a   Van der Ploeg, A T ^b   Van Doorn, P A ^a   Wokke, J H J ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Acid glucosidase; Disease progression; Glycogen storage disease type II; Late onset; Pompe disease

Indexed keywords

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; FOLLOW UP; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; LUNG FUNCTION; MALE; MUSCLE STRENGTH; MUSCLE WEAKNESS; PATIENT MONITORING; PRIORITY JOURNAL; SKELETAL MUSCLE; WHEELCHAIR;

ACTIVITIES OF DAILY LIVING; ADULT; AGE OF ONSET; AGED; COMORBIDITY; COST OF ILLNESS; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MUSCLE WEAKNESS; MUSCLE, SKELETAL; RESPIRATORY PARALYSIS; TIME FACTORS; VENTILATORS, MECHANICAL; WHEELCHAIRS;

EID: 59149086832     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2008.11.007     Document Type: Article

References (28)

1. Ausems M.G., Verbiest J., Hermans M.P., et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet 7 (1999) 713-716
2. Hirschhorn R., and Reuser A.J.J. Glycogen storage disease type II: acid a-glucosidase (acid maltase) deficiency. Scriver: The metabolic and molecular basis of inherited disease. 8th ed. (2001), McGraw-Hill, New York 3389-3420
3. Martiniuk F., Chen A., Mack A., et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet 79 (1998) 69-72
4. Kishnani P.S., Hwu W.L., Mandel H., Nicolino M., Yong F., and Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148 (2006) 671-676
5. Van den Hout H.M., Hop W., Van Diggelen O.P., et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112 (2003) 332-340
6. Hagemans M.L., Winkel L.P., Hop W.C., Reuser A.J., van Doorn P.A., and van der Ploeg A.T. Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology 64 (2005) 2139-2141
7. Winkel L.P., Hagemans M.L., van Doorn P.A., et al. The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol 252 (2005) 875-884
8. Engel A.G., Gomez M.R., Seybold M.E., and Lambert E.H. The spectrum and diagnosis of acid maltase deficiency. Neurology 23 (1973) 95-106
9. Amalfitano A., Bengur A.R., Morse R.P., et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 3 (2001) 132-138
10. Kishnani P.S., Nicolino M., Voit T., et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 149 (2006) 89-97
11. Kishnani P.S., Corzo D., Nicolino M., et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68 (2007) 99-109
12. Klinge L., Straub V., Neudorf U., et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 15 (2005) 24-31
13. Van den Hout H., Reuser A.J., Vulto A.G., Loonen M.C., Cromme-Dijkhuis A., and van der Ploeg A.T. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 356 (2000) 397-398
14. Van den Hout J.M., Kamphoven J.H., Winkel L.P., et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113 (2004) e448-e457
15. Winkel L.P., Van den Hout J.M., Kamphoven J.H., et al. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol 55 (2004) 495-502
16. Pellegrini N., Laforet P., Orlikowski D., et al. Respiratory insufficiency and limb muscle weakness in adults with Pompe's disease. Eur Respir J 26 (2005) 1024-1031
17. Hagemans M.L., Hop W.J., van Doorn P.A., Reuser A.J., and van der Ploeg A.T. Course of disability and respiratory function in untreated late-onset Pompe disease. Neurology 66 (2006) 581-583
18. Laforet P., Nicolino M., Eymard P.B., et al. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology 55 (2000) 1122-1128
19. Muller-Felber W., Horvath R., Gempel K., et al. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 17 (2007) 698-706
20. Wokke J.H., Ausems M.G., Van den Boogaard M.J., et al. Genotype-phenotype correlation in adult-onset acid maltase deficiency. Ann Neurol 38 (1995) 450-454
21. Pompe J.C. Over idiopathische hypertrofie van het hart. Ned Tijdschr Geneeskd 76 (1932) 304-311
22. Burghaus L., Liu W., Neuen-Jacob E., Gempel K., and Haupt W.F. [Glycogenesis Type II (M. Pompe). Selective failure of the respiratory musculature - a rare first symptom]. Nervenarzt 77 (2006) 181-186
23. Mellies U., Ragette R., Schwake C., Baethmann M., Voit T., and Teschler H. Sleep-disordered breathing and respiratory failure in acid maltase deficiency. Neurology 57 (2001) 1290-1295
24. Van der Ploeg A.T. Monitoring of pulmonary function in Pompe disease: a muscle disease with new therapeutic perspectives. Eur Respir J 26 (2005) 984-985
25. Kroos M.A., Van der K.M., Van Diggelen O.P., et al. Glycogen storage disease type II: frequency of three common mutant alleles and their associated clinical phenotypes studied in 121 patients. J Med Genet 32 (1995) 836-837
26. Montalvo A.L., Bembi B., Donnarumma M., et al. Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat 27 (2006) 999-1006
27. Kroos M.A., Pomponio R.J., Hagemans M.L., et al. Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype. Neurology 68 (2007) 110-115
28. Huie M.L., Chen A.S., Tsujino S., et al. Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T→G) mutation in a majority of patients and a novel IVS10 (+1GT→CT) mutation. Hum Mol Genet 3 (1994) 2231-2236